Advances in Research on Pharmacological Effect of Astragaloside Ⅳ on Cardiovascular and Cerebrovascular Diseases

Xiang-lin KONG; Qin LYU; Yun-lun LI; Dong-fang KAN; Ke PEI; Qing-feng BU; Ya-qi ZHANG; Ji-biao WU

doi:10.13422/j.cnki.syfjx.20210144

您当前的位置：

首页 >

文章列表页 >

Advances in Research on Pharmacological Effect of Astragaloside Ⅳ on Cardiovascular and Cerebrovascular Diseases

更新时间：2021-12-03

- Advances in Research on Pharmacological Effect of Astragaloside Ⅳ on Cardiovascular and Cerebrovascular Diseases
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 27, Issue 2, Pages: 218-223(2021)
- 作者机构：
  
  1.山东中医药大学，济南 250355
  2.泰安市中医医院，泰安 271000
  3.山东中医药高等专科学校，烟台 264010
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.20210144
  CLC： R2-0;R289;R285.5;R825.4
- Received：31 August 2020，
  
  Published Online：24 November 2020，
  
  Published：20 January 2021
- 稿件说明：
移动端阅览
孔祥琳,吕琴,李运伦等.黄芪甲苷对心脑血管疾病的现代药理作用研究进展[J].中国实验方剂学杂志,2021,27(02):218-223.

KONG Xiang-lin,LYU Qin,LI Yun-lun,et al.Advances in Research on Pharmacological Effect of Astragaloside Ⅳ on Cardiovascular and Cerebrovascular Diseases[J].Chinese Journal of Experimental Traditional Medical Formulae,2021,27(02):218-223.
孔祥琳,吕琴,李运伦等.黄芪甲苷对心脑血管疾病的现代药理作用研究进展[J].中国实验方剂学杂志,2021,27(02):218-223. DOI： 10.13422/j.cnki.syfjx.20210144.

KONG Xiang-lin,LYU Qin,LI Yun-lun,et al.Advances in Research on Pharmacological Effect of Astragaloside Ⅳ on Cardiovascular and Cerebrovascular Diseases[J].Chinese Journal of Experimental Traditional Medical Formulae,2021,27(02):218-223. DOI： 10.13422/j.cnki.syfjx.20210144.

摘要

黄芪有补气固表、利尿托毒、排脓、敛疮生肌之效，不仅用于肺脾气虚、脾虚泄泻等证候，大剂量使用还可用于中风、胸痹等疾病，发挥补气活血功用。由于黄芪化学成分复杂，药理作用多样，其发挥补气活血的主要作用物质基础目前尚未明确。黄芪甲苷是其主要活性成分之一，近几年，国内外对黄芪甲苷的研究越来越多，报道显示，其具有增强机体免疫功能、强心降压、降低血糖、利尿、抗衰老和抗疲劳等药用价值，具有广泛的药理活性。其中，尤其对心脑血管疾病的作用日益受到人们重视。心脑血管疾病是由于血液黏稠、动脉粥样硬化、高血压、高脂血症等导致的心脏、大脑及全身组织发生的缺血性或出血性疾病，包括心血管和脑血管疾病。此类疾病严重威胁人类，是全球主要的病死原因。目前以西药治疗为主，不良反应多，远期效果预后不佳。中医认为气血失衡是该类疾病基本病机，气虚血瘀型较为常见，常采用益气活血之法，气血以流，经络所通。目前，黄芪甲苷在治疗心脑血管疾病方面已进行了多项研究，并取得了一定的成果，本文综述近年黄芪甲苷在治疗心脑血管疾病中发挥的药理活性，为探求黄芪甲苷是否是黄芪补气活血主要作用物质基础寻找理论依据，也为创新中医中药的药物研发奠定理论基础与实践指导。

Abstract

Astragalus membranaceus has the effect of tonifying Qi and solid surface， diuretic support poison， discharging pus and astringent sores to produce muscle. It is not only used for syndromes such as deficiency of lung and temper， deficiency of spleen and diarrhea， but also for stroke， chest obstruction and other diseases. Due to the complex chemical composition and diverse pharmacological effect of Astragalus membranaceus， and the main role in invigorating qi and activating blood circulation has not been clarified. Astragaloside Ⅳ is one of its main active ingredients. In recent years， more and more studies on Astragaloside Ⅳ have been conducted at home and abroad. It has been reported that it has the medicinal value of enhancing immune function， strengthening heart and lowerin blood glucose， diuresis， anti-aging and anti-fatigue， et al， and has extensive pharmacological activity. Among them， the role of cardiovascular and cerebrovascular diseases in particular has attracted increasing attention. Cardiovascular and cerebrovascular diseases are ischemic or hemorrhagic diseases occurring in the heart， brain and systemic tissues due to blood viscosity， atherosclerosis， hypertension， hyperlipidemia， etc.， including cardiovascular and cerebrovascular diseases. Such diseases are a serious threat to mankind and are the leading cause of death worldwide. At present， western medicine is the main treatment， with many adverse reactions and poor long-term prognosis. TCM believes that the imbalance of qi and blood is the basic pathogenesis of this kind of disease. Qi deficiency and blood stasis are more common.At present， Astragaloside Ⅳ in the treatment of cardiovascular and cerebrovascular diseases in a number of studies， and achieved some results， but this review in recent years， Astragaloside Ⅳ in the treatment of cardiovascular and cerebrovascular diseases play the pharmacological activity， in order to explore whether Astragaloside Ⅳ is the main role of astragalus qi to find a theoretical basis for material basis， but also for the innovation of traditional Chinese medicine drug research and development of theoretical basis and practical guidance.

关键词

Keywords

references

赵冬 . 新中国成立70年来我国人群血脂流行病学研究回顾与进展［J］. 中国医药， 2019 ， 14 （ 10 ）： 1441 - 1444 .

胡皓 . 从“络脉空虚”论治缺血性心脑血管病［J］. 中西医结合心血管病电子杂志， 2018 ， 6 （ 23 ）： 17 - 19 .

王燕华 . 冠心病不稳定型心绞痛中医证型与冠状动脉Gensini评分、血浆促动脉硬化指数（AIP）相关性研究［D］. 福州：福建中医药大学， 2019 .

蒋微，蒋式骊，刘平 . 黄芪甲苷的药理作用研究进展［J］. 中华中医药学刊， 2019 ， 37 （ 9 ）： 2121 - 2124 .

CAO J Y ， CHEN Z Y ， ZHU Y R ， et al . Huangqi-Honghua combination and its main components ameliorate cerebral infarction with Qi deficiency and blood stasis syndrome by antioxidant action in rats ［J］. J Ethnopharmacol ， 2014 ， 155 ： 1053 - 60 .

SUN B ， RUI R P ， PAN H Y ， et al . Effect of combined use of astragaloside Ⅳ and Atorvastatin （AV） on expression of PPAR- γ and inflammation-associated cytokines in atherosclerosis rats ［J］. Med Sci Monit ， 2018 ， 24 ： 6229 - 6236 .

CHU H L ， HUANG C Y ， GAO Z D ， et al . Reduction of ischemic brain edema by combined use of paeoniflorin and astragaloside Ⅳ via down-regulating connexin 43 ［J］. Phytother Res ， 2017 ， 31 ： 1410 - 1418 .

赵剑，刘广辉，梁亮，等 . 黄芪甲苷对大鼠脑出血后脑水肿及水通道蛋白4表达的影响［J］. 宁夏医科大学学报， 2015 （ 8 ）： 4，27 - 30，34 .

ZHENG J ， YIN F ， JIN G Q ， et al . In vitro neuroprotection of rat hippocampal neurons by manninotriose and astragaloside Ⅳ against corticosterone-induced toxicity ［J］. Molecules ， 2018 ， 23 ： 3329 .

KIM S ， KANG I H ， NAM J B ， et al . Ameliorating the effect of astragaloside Ⅳ on learning and memory deficit after chronic cerebral hypoperfusion in rats ［J］. Molecules ， 2015 ， 20 ： 1904 - 21 .

SUN Q ， JIA N ， WANG W ， et al . Protective effects of astragaloside Ⅳ against amyloid beta1-42 neurotoxicity by inhibiting the mitochondrial permeability transition pore opening ［J］. PLoS One ， 2014 ， 9 ： e98866 .

ZHU X M ， CHEN Y ， DU Y P ， et al . Astragaloside Ⅳ attenuates penicillin-induced epilepsy via inhibiting activation of the MAPK signaling pathway ［J］. Mol Med Rep ， 2018 ， 17 （ 1 ）： 643 - 647 .

LI B ， WANG F ， LIU N T ， et al . Astragaloside Ⅳ inhibits progression of glioma via blocking MAPK/ERK signaling pathway ［J］. Biochem Biophys Res Commun ， 2017 ， 491 ： 98 - 103 .

WANG X ， WANG Y ， HU J P ， et al . Astragaloside Ⅳ，a natural PPAR γ agonist，reduces A production in Alzheimer's disease through inhibition of BACE1 ［J］. Mol Neurobiol ， 2017 ， 54 ： 2939 - 2949 .

YIN F ， ZHOU H ， FANG Y ， et al . Astragaloside Ⅳ alleviates ischemia reperfusion-induced apoptosis by inhibiting the activation of key factors in death receptor pathway and mitochondrial pathway ［J］. J Ethnopharmacol ， 2019 ， 248 ： 112319 .

GONG L ， CHANG H ， ZHANG J ， et al . Astragaloside Ⅳ protects rat cardiomyocytes from hypoxia-induced injury by down-regulation of miR-23a and miR-92a ［J］. Cell Physiol Biochem ， 2018 ， 49 ： 2240 - 2253 .

LU M ， TANG F ， ZHANG J ， et al . Astragaloside Ⅳ attenuates injury caused by myocardial ischemia/reperfusion in rats via regulation of toll-like receptor 4/nuclear factor- κ B signaling pathway ［J］. Phytother Res ， 2015 ， 29 ： 99 - 606 .

NIE P ， MENG F ， ZHANG J ， et al . Astragaloside Ⅳ exerts a myocardial protective effect against cardiac hypertrophy in rats，partially via activating the Nrf2/HO-1 signaling pathway ［J］. Oxid Med Cell Longev ， 2019 ， doi： 10.1155/2019/4625912 http://dx.doi.org/10.1155/2019/4625912 .

李家深，朱晓宇，卢美丽，等 . 电针和黄芪甲苷联合干预对心肌纤维化大鼠心肌肥大和TGF- β 1 /Smad信号的影响［J］. 针刺研究， 2017 ， 42 ： 477 - 81 .

LU Y ， LI S ， WU H ， et al . Beneficial effects of astragaloside Ⅳ against angiotensin Ⅱ-induced mitochondrial dysfunction in rat vascular smooth muscle cells ［J］. Int J Mol Med ， 2015 ， 36 ： 1223 - 1232 .

GUAN F Y ， YANG S J ， LIU J X ， et al . Effect of Astragaloside Ⅳ against rat myocardial cell apoptosis induced by oxidative stress via mitochondrial ATP-sensitive potassium channels ［J］. Mol Med Rep ， 2015 ， 12 ： 371 - 376 .

SI J ， WANG N ， WANG H ， et al . HIF-1 α signaling activation by post-ischemia treatment with astragaloside Ⅳ attenuates myocardial ischemia-reperfusion injury ［J］. PLoS One ， 2014 ， 9 ： e107832 .

WEI D ， XU H ， GAI X ， et al . Astragaloside Ⅳ alleviates myocardial ischemia-reperfusion injury in rats through regulating PI3K/Akt/GSK-3 β signaling pathways ［J］. Acta Cir Bras ， 2019 ， 34 ： e201900708 .

ZHANG S ， TANG F ， YANG Y ， et al . Astragaloside Ⅳ protects against isoproterenol-induced cardiac hypertrophy by regulating NF- κ B/PGC-1 α signaling mediated energy biosynthesis ［J］. PLoS One ， 2015 ， 10 ： e0118759 .

TU L ， PAN C S ， WEI X H ， et al . Astragaloside Ⅳ protects heart from ischemia and reperfusion injury via energy regulation mechanisms ［J］. Microcirculation ， 2013 ， 20 ： 736 - 747 .

YIN B ， HOU X W ， LU M L ， Astragaloside Ⅳ attenuates myocardial ischemia/reperfusion injury in rats via inhibition of calcium-sensing receptor-mediated apoptotic signaling pathways ［J］. Acta Pharmacol Sin ， 2019 ， 40 ： 599 - 607 .

LU M ， LENG B ， HE X ， et al . Calcium sensing receptor-related pathway contributes to cardiac injury and the mechanism of astragaloside Ⅳ on cardioprotection ［J］. Front Pharmacol ， 2018 ， 9 ： 1163 .

赵晓平 . 中西医结合神经外科研究与实践［M］. 西安：西安交通大学出版社， 2017 ： 55 .

ZHU Z S ， LI J Y ， ZHANG X R . Astragaloside Ⅳ protects against oxidized low-density lipoprotein （ox-LDL）-induced endothelial cell injury by reducing oxidative stress and inflammation ［J］. Med Sci Monit ， 2019 ， 25 ： 2132 - 2140 .

NIE Q ， ZHU L ， ZHANG L ， et al . Astragaloside Ⅳ protects against hyperglycemia-induced vascular endothelial dysfunction by inhibiting oxidative stress and Calpain-1 activation ［J］. Life Sci ， 2019 ， 232 ： 116662 .

YOU L Z ， FANG Z H ， SHEN G M ， et al . Astragaloside Ⅳ prevents high glucose‑induced cell apoptosis and inflammatory reactions through inhibition of the JNK pathway in human umbilical vein endothelial cells ［J］. Mol Med Rep ， 2019 ， 19 ： 1603 - 1612 .

战云，张英杰，冷彬 . 黄芪甲苷通过TLR4/NF- κ B通路改善脂多糖诱导的急性血管内皮损伤［J］. 中药药理与临床， 2018 （ 3 ）： 77 - 80

尤良震 . 黄芪甲苷通过JNK信号通路对高糖诱导的人脐静脉内皮细胞炎性损伤的保护作用机制研究［D］. 合肥：安徽中医药大学， 2017 .

QIAN W B ， CAI X R ， QIAN Q H ， et al . Astragaloside Ⅳ protects endothelial progenitor cells from the damage of ox-LDL via the LOX-1/NLRP3 inflammasome pathway ［J］. Drug Des Devel Ther ， 2019 ， 13 ： 2579 - 2589 .

WANG S ， CHEN J ， FU Y ， et al . Promotion of astragaloside Ⅳ for EA-hy926 cell proliferation and angiogenic activity via ERK1/2 pathway ［J］. J Nanosci Nanotechnol ， 2015 ， 15 ： 4239 - 4244 .

司静文 . 基于血管新生与成熟的HIF-1 α 信号机制揭示黄芪甲苷Ⅳ治疗心肌梗死的新机制［D］. 西安：第四军医大学， 2014 .

SONG Z ， WEI D ， CHEN Y ， et al . Association of astragaloside Ⅳ-inhibited autophagy and mineralization in vascular smooth muscle cells with lncRNA H19 and DUSP5-mediated ERK signaling ［J］. Toxicol Appl Pharmacol ， 2019 ， 364 ： 45 - 54 .

LENG B ， TANG F ， LU M ， et al . Astragaloside Ⅳ improves vascular endothelial dysfunction by inhibiting the TLR4/NF- κ B signaling pathway ［J］. Life Sci ， 2018 ， 209 ： 111 - 121 .

曹献英，琳琳 . 应用生理学［M］. 中国科学技术大学出版社， 2015 ： 45 .

张乐裕，刘晨阳，于顾然 . 黄芪甲苷对A β 1-42 诱导的体外血脑屏障模型损伤的影响及机制探究［J］. 中草药， 2018 ， 49 （ 17 ）： 4099 - 4105 .

LI H L ， WANG P ， HUANG F ， et al . Astragaloside Ⅳ protects blood-brain barrier integrity from LPS-induced disruption via activating Nrf2 antioxidant signaling pathway in mice ［J］. Toxicol Appl Pharmacol ， 2018 ， 340 ： 58 - 66 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Analysis of Mechanism of Astragaloside Ⅳ in Regulating Ferroptosis Through SLC7A11/GPX4 Pathway Against Vascular Smooth Muscle Cell Proliferation

Mechanism of Astragaloside Ⅳ in Regulating PI3K/Akt Molecular Pathway in Prevention and Treatment of Diabetes Complications： A Review

Molecular Mechanism of Action of Astragaloside Ⅳ in Modulating Pyroptosis to Attenuate Intestinal Ischemia-reperfusion Injury Based on Experimental Validation

Mechanism of Astragaloside Ⅳ on db/db Mice with Type 2 Diabetes Mellitus and Non-alcoholic Fatty Liver Disease Based on AMPK Signaling Pathway

Astragaloside Ⅳ Induces Autophagy and Apoptosis in Nasopharyngeal Carcinoma Cells via PI3K/Akt/mTOR Pathway

Related Author

LI Guoting

YANG Changchao

LIU Lin

LI Weikang

ZHAO Zixian

SHEN Quan

ZHAO Jingshan

HU Kexin

Related Institution

Hebei Key Laboratory of Traditional Chinese Medicine（TCM） Research on Cardiocerebrovascular Disease，TCM Processing Technology Innovation Center of Hebei Province，College of Pharmacy， Hebei University of Chinese Medicine

Anhui University of Chinese Medicine

The First Affiliated Hospital of Anhui University of Chinese Medicine

Key Laboratory of Xin'an Medical Education Department，Anhui University of Chinese Medicine

The First Hospital of Lanzhou University

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰